In summary, this small, retrospective pilot suggests that higher FOXP3, PD 1, and CD32B (relative to CD8 or CD19) levels are associated with adverse pathological features and shorter DFS in resectable lung adenocarcinoma. Here, FCGR2B is linked to lung adenocarcinoma.